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ABSTRACT
Normal pregnancy is a hypercoaguable state in and of itself. Evidence has shown that 
platelets may play a role in the pathogenesis and complications of preeclampsia. The 
objective of this study is to compare the presence of circulating activated platelets in 
normal pregnancy and preeclampsia. The subjects’ blood was fixed, washed, incubated 
with antibodies (which detect platelets and activation of platelets), and evaluated using 
flow cytometry. Results of this study showed pregnant subjects (normal and 
preeclamptic) to have an increased percentage of activated platelets over non-pregnant 
subjects. Increased platelet activation may account for platelet consumption and bleeding 
complications in preeclamptic patients.
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PREFACE
Definition of Terms
Abrupto Placentae -  Separation of the placenta implanted in normal position in a 
pregnancy of 20 weeks or more during labor before delivery of the fetus.
Aggregation -  An accumulation of substances, objects, or individuals, as in the clumping 
of blood cells or the clustering of clients with the same disorder.
Angiotensin -  A polypeptide in the blood that causes vasoconstriction, increased blood 
pressure, and the release of aldosterone fiom the adrenal cortex.
Catecholamine -  A neurological chemical
Cerebral Hemorrhage -  A hemorrhage from a blood vessel in the brain
Coagulation -  The process of transforming a liquid into a solid, especially of the blood.
Convulsion -  A hyperexcitation of neurons in the brain leading to a sudden, violent 
involuntary series o f contractions of a group of muscles.
Cytokine - One of a large group of low molecular weight proteins secreted by various 
cell types and involved in cell-to-cell communication.
Diastolic Blood Pressure -  The blood pressure at the instant of maximum cardiac 
relaxation.
Disseminated Intravascular Coagulation (DIC) -  A grave coagulopathy resulting hom the 
overstimulation of clotting and anticlotting processes in response to disease or injury.
Diuretic -  A drug that promotes the formation and excretion of urine.
Eclampsia -  The gravest form of pregnancy-induced hypertension. It is characterized by 
grand mal seizure, coma, hypertension, proteinuria, and edema.
Edema -  The abnormal accumulation of fluid in interstitial spaces of tissue.
Endoplasmic Reticulum -  An extensive networic o f membrane-enclosed tubles in the 
cytoplasm of cells. The structure functions the synthesis of proteins and lipids and in the 
transport of these metabolites within the cell.
Endothelin -  Any o f a group of vasoconstrictive peptides produced by endothelial cells
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Endothelium -  The layer o f simple squamous epithelial cells that lines the heart, the 
blood and lymph vessels, and the serous cavities of the body.
Epigastric -  Pertaining to the epigastrium, the area above the stomach
Fetal Hvdrops (hydrops fetalis) -  Massive edema in the fetus or newborn, usually in 
association with severe erythroblastosis fetalis.
Fibrin -  A stringy insoluble protein produced by the action of thrombin on fibrinogen in 
the clotting process. Fibrin is responsible for the semisolid character of a blood clot.
Flow Cvtometer -  A Becton Dickson Flow Cytometer is used for this study. This 
machine is equipped with Cellquest software and is used to identify platelets and platelets 
tagged by antibody.
Gestation -  in viviparous animal the period ftom the fertilization of the ovum until 
birth.. in humans die average duration is 266 days.
Glomerular Filtration Rate -  A kidney function test in which results can be determined 
from the amount of ultrafiltrate formed by plasma flowing thorough the glomeruli of the 
kidney. It may be calculated from insulin and creatinine clearance, serum creatinine and 
blood urea nitrogen. Normal values average 170 L/day for men and 150/day for women.
Glycoproteins -  Any of the large group of conjugated proteins in which the nonprotein 
substance is a carbohydrate.
Gravida -  A woman who is pregnant.
HELL? Syndrome -  Acronym for a form of severe preeclampsia, a hypertensive 
complication of late pregnancy. The letters stand fbrAemolysis, elevated /iver function, 
and law platelet level.
Hemolysis -  The breakdown of red blood cells and the release of hemoglobin.
Hemorrfiage -  A loss of a large amount of blood in a short period, either externally or 
internally.
Hemostasis -  The termination of bleeding by mechanical or chemical means or by the 
complex coagulation process of the body, which consists of vasoconstriction, platelet 
aggregation, and thrombin and fibrin synthesis.
Hepatic -  Pertaining to the liver.
Hydatidiform Mole -  An interuterine neoplastic mass of gr^elike enlarged chorionic 
villi
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Hvperreflexia -  Increased reflex reactions
Hypertension -  A common, often asymptomatic disorder characterized by elevated blood 
pressure persistently exceeding 140/90mm Hg.
Hypertensive enceohaloDathv -  A set of symptoms, including headache, convulsions, and 
coma, associated with glomerulonephritis.
Hvpoalbuminemia -  A condition of abnormally low levels of albumin in the blood.
Ischemia -  A decreased supply of oxygenated blood to a body organ or part.
Jaundice -  A yellow discoloration of the skin, mucous membranes, and sclerae of the 
eyes, caused by greater than normal amounts of bilirubin in the blood.
Megakaryocytes -  An extremely large bone marrow cell measuring between 35 and 160 
/un in diameter and having a nucleus with many lobes. Magakaryocytes are essential for 
the production and proliferation of platelets in the marrow and are normally not present in 
the circulating blood.
Microangiophilic Hemolvtic Anemia -  A disorder in which narrowing or obstruction of 
small blood vessels results in distortion and fragmentation of erythrocytes, hemolysis, 
and anemia.
Mitochondria -  An organelle within the cytoplasm that function in cellular metabolism 
and respiration. Mitochondria provide the principle source of cellular energy thorough 
oxidative phosphorylation and adenosine triphosphate synthesis.
Morbidity -  An illness or abnormal condition or quality; the rate at which an illness or 
abnormality occurs
Mortality -  The condition of being subject to death; the death rate.
Multifactoral Polvgenetic Inheritance -  The tendency to develop a physical ^ pearance 
disease or condition that is a condition of many genetic and environmental factors, such 
as stature and blood pressure.
Norepinephrine -  An adrenergic hormone that acts to increase blood pressure by 
vasoconstriction but does not affect cardiac output.
Nulliparity -  A woman who has not given birth to a viable infant.
Papilledema -  Swelling of the optic disc, visible on ophthalmoscopic examination of the 
fundus of the eye, caused by increase in intracranial pressure.
Parity -  The classification of a woman by the number o f live-bom children and stillbirths 
she has delivered at more than 20 weeks gestation.
Pathogenesis -  The source of cause of an illness or abnormal condition.
Pathophysiology -  The study of the biologic and physical manifestations of disease as 
they correlate with the underlying abnormalities and physiologic disturbances. It explains 
the processes within the body that result in the signs and symptoms of a disease.
Perinatal -  Pertaining to the time and process of giving birth or being bom.
Platelet -  The smallest cells in the blood. They are formed in the red bone marrow and 
some are stored in the spleen. Platelets are disk-shtq)ed, contain no hemoglobin, and are 
essential for the coagulation of blood and in maintenance of hemostasis.
Preeclampsia -  An abnormal condition of pregnancy characterized by the onset of acute 
hypertension after the twenty-fourth week of gestation. The classic triad of preeclampsia 
is hypertension, proteinuria, and edema. The cause the disease remains unknown. It 
occurs in 5-7% of pregnancies, most often in primigravidas. Termination of the 
pregnancy results in resolution of the signs and symptoms of the disease and in healing of 
the renal lesion. The most serious complication is eclampsia, which can result in maternal 
and fetal death. Formerly called Toxemia of Pregnancy.
Prostacvcline -  A prostaglandin that is a biologically active product o f arachidonic acid 
metabolism in human vascular walls and a potent inhibitor of platelet aggregation. It 
inhibits the vasoconstrictor effect of angiotensin and stimulates renin release.
Proteinuria -  The presence in the urine of abnormally large quantities of protein, usually 
albumin.
Pulmonary Edema -  The accumulation of extravascular fluid in lung tissues and alveoli. 
Renal- Pertaining to the kidney.
Serotonin -  A naturally occurring derivative of tryptophan found in platelets and in cells 
of the brain and the intestine. Serotonin is released from platelets on damage to the blood 
vessel walls. It acts as a potent vasoconstrictor.
Spina Bifida -  A congenital neural tube defect characterized by a developmental anomaly 
in the posterior vertebral arch.
Systolic Blood Pressure -  The blood pressure measured during the period of ventricular 
contraction (systole).
XI
Thrombin -  An enzyme formed from prothrombin, calcium, and thromoplastin in plasma 
during the clotting process. Thrombin causes fibrinogen to change to fibrin, which is 
essential in the formation of a clot.
Thrombocvtonenia -  Reduction in the number of platelets. There may be a decreased 
production o f platelets, decreased survival of platelets, and increases consumption of 
platelets.
Thromboxanes -  Compounds synthesized by platelets and other cells that cause platelet 
aggregation and vasoconstriction.
Tonic/clonic seizure -  An epileptic seizure characterized by a generalized involuntary 
muscular contraction and cessation of respiration followed by tonic and clonic spasms of 
the muscles.
Vasoactive -  Tending to cause vasodilation or vasoconstriction 
Vasoconstriction -  A narrowing of the lumen of any blood vessel 
Vasodilation -  An increase in the diameter of a blood vessel.
Vasopressin -  AKA Antidiuretic Hormone. A hormone that decreases the production of 
urine by increasing the reabsorption of water by the renal tubules.
Vasospasm -  A spasm in a blood vessel
Definitions are taken from Mosby’s Medical, Nursing, and Allied Health Dictionary. Fifth 
edition. 1998.
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CHAPTER 1 
INTRODUCTION
Preeclampsia, otherwise known as toxemia of pregnancy or pregnancy induced 
hypertension, is a problem in pregnant women consisting of three primary symptoms: 
hypertension (high blood pressure), edema (swelling), and proteinuria (protein in the 
urine). The cause and pathogenesis of preeclampsia is unknown. It usually develops after 
the twentieth week of gestation and the only curative treatment is delivery of the baby. 
When the fetus has not matured enough to deliver and live viably outside of the mother, 
preeclampsia is managed with bed rest, medications to lower the blood pressure, and 
medications to prevent eclamptic seizures while the baby matures (Fauci et al 1998, 
Cunningham et al 1997, Barron et al 2000, Witlin et al 1999, Witlin et al 2000).
Women who are younger than twenty years or older than thirty-five years during 
pregnancy are at a greater risk of developing preeclampsia (Cunningham et al 1997). 
Other risk factors include how many children they have had, preexisting hypertension, 
diabetes mellitus, renal disease, vascular disease, and a previous history or family history 
of preeclampsia. There are currently no tests available to predict preeclampsia during 
pregnancy (Fauci et al 1998, Barron et al 2000, Lenfant et al 1990, Burrow, Duffy 1999, 
Cunningham et al 1997, Redman 1992).
Preeclampsia affects 2 to 10% of all pregnancies in the United States and is 
responsible for SO to 70% of hypertension in pregnancy. Preeclampsia is the most 
common cause of perinatal morbidity and mortality. It accounts for 35 to 300 deaths per 
1000 births each year. It is also responsible for at least 76,000 deaths each year
world wide (Barron et al 2000, Konijnenberg A et al 1997 Feb, Cunningham et al 1997, 
Redman 1992). As demonstrated, preeclampsia is a serious complication in pregnancy.
Background
Twenty percent of women with preeclampsia develop bleeding problems during 
delivery that present serious risks to the mother and the infant. Platelets play a vital role 
in coagulation (the blood clotting mechanism), which stops profuse bleeding. 
Hematological changes occur during preeclampsia in both coagulation and platelet 
aggregation. These platelet changes are thought to be related to the bleeding problems 
experienced during delivery. It is believed that platelets may play an early pathogenic 
role in preeclampsia (Cunningham et al 1997).
Platelets play a crucial role in hemostasis by providing a surface where 
coagulation can take place and by aggregating together to form a clot. They are anuclear 
cells that are produced in the bone marrow by megakaryocytes. Upon stimulation, 
platelets release different granules and activate the coagulation system. The response is 
graded and depends on the extent of damage as to how much and which granules are 
released (Kumar et al 1997, Me Cance KL, Huether SE, 1998, Silverthom et al 1998).
For this study blood samples are drawn from the non-pregnant, normal pregnant, 
and preeclamptic groups of women and fixed to prevent further activation from that 
which had already occurred in vivo. The samples are taken to the flow cytometry lab 
where the platelets are separated from the rest of the cells and serum. After the platelets 
have been separated and washed, they are tagged with a fluorescent antibody to the 
normal proteins on the plasma cell surface. The markers are used to look for surface
proteins that identify the cell as a platelet as well as those that are present on the surface 
of activated platelets. The tagged platelets are then run through the flow cytometer, where 
the platelets are analyzed and the degree of fluorescence is recorded.
Flow cytometry quickly measures specific characteristics of a large number of 
individual cells. Before being run through the machine, the cell proteins are labeled with 
a fluorescent monoclonal antibody. Suspended cells can pass through the flow 
cytometer’s focused laser beam at a rate of 1,000 to 10,000 per minute. The fluorescent 
antibodies are excited by a wavelength of light and a detector processes the light given 
off and the light scattered by the cells. These numbers and graphs show up on the 
computer monitor for the researchers to see instantly (Coon et al 1987, Leytin et al 2000, 
Shattil et al 1987).
The results obtained in the preeclamptic sample are compared to the results of 
previous studies performed in normal non-pregnant females and normal pregnant 
females. The goal of this study is to prove the hypothesis that the surface proteins on 
platelets of preeclamptic women are in a more activated state than in non-pregnant and 
normal pregnant women.
Problem Statement
Preeclampsia occurs in 2 to 10% of pregnancies and many of these lead to fetal 
and maternal morbidity and mortality (Cunningham et al 1997). The diagnosis is difficult 
at best and detection usually does not occur until the final trimester of pregnancy. There 
remains no definitive test to predict preeclampsia.
Twenty percent of women with preeclampsia experience bleeding problems
during their delivery. This study is investigating whether or not a test looking at the 
platelets for activation could be predictive of preeclampsia or could be predictive of 
bleeding problems at the time of delivery.
If platelets are activated early in pregnancy in women who have preeclampsia the 
platelets may be used up prior to delivery, leading to an insufficient amount o f platelets 
remaining to allow clotting and hemostasis to occur. This could be the reason why some 
preeclamptic women have bleeding problems at delivery. If preeclampsia can be 
detected at an earlier stage by looking at the platelets for activation, the potential for 
preventing bleeding problems exists. If bleeding cannot be prevented, at the least the 
medical personnel can be better prepared at the time of delivery for the probability of 
bleeding to occur.
Purpose
The purpose of this study is to identify the surface proteins for activation on the 
platelet cells and to determine the amount of these surface proteins to discover what 
percentage of the platelets are activated in preeclamptic women. When these have been 
identified they will be compared to the percentage of activated surface markers in non­
pregnant and normal pregnant women to see if there is an increase in activation of the 
platelets in preeclamptic women. Any differences noted could attribute to the bleeding 
problem experienced by 20% of women with preeclampsia.
The goal of this study is to prove the hypothesis that the surface proteins on the 
platelets of preeclamptic women are such that the platelet is circulating in a more 
activated state than in non-pregnant and normal pregnant women. This could prove as an
early detection test for preeclampsia. If the platelets are more activated the ultimate goal 
is to use this information to develop a test for determining those with preeclampsia who 
will develop bleeding problems.
Significance of the Problem
Preeclampsia, in and of itself, can be a serious problem leading to increased 
morbidity and mortality for the mother and fetus (Cunningham et al 1997). There is 
currently no test for early detection of preeclampsia, so the disorder is commonly not 
discovered until the third trimester, when the three main symptoms, hypertension, edema, 
and proteinuria, are conunonly picked up. Alterations in blood vessels in the placenta are 
seen as the vascular supply of the placenta is being developed (Burrow, Dufly 1999, 
McCrae et al 1992). Changes in platelets, including activation of platelets, may occur as 
early as the second trimester when these vascular changes occur. A test for these changes, 
if they occur earlier in pregnancy, may lead to earlier detection of preeclampsia.
One in five women with pre-eclampsia develop bleeding problems during 
pregnancy but currently there is no way to determine which women with preeclampsia 
will develop these bleeding problems and which women will not. By looking at the 
activation of circulating platelets in non-pregnant, normal pregnant, and preeclamptic 
women and determining the level of activation a difference of activation is expected to be 
discovered. From this information a test can be developed to determine who will develop 
bleeding problems during delivery. By being able to predict who will have problems with 
bleeding, medical staff will be better prepared to control the bleeding that occurs at 
delivery or have the option of doing a c-section to control the bleeding. This will result in
less risk to the mother and the baby and decrease the morbidity and mortality of 
preeclampsia.
Hypothesis
From previous studies performed by GVSU students and Dr. Theresa Bacon- 
Baguley, it has been discovered that the activation of platelets is different in women who 
are pregnant than those of women who are not pregnant. This current research is looking 
at the differences in platelet activation in women with preeclampsia compared to non­
pregnant and normal pregnant women. The goal of this study is to prove the hypothesis 
that the surface proteins on platelets of preeclamptic women are in a more activated state 
than in non-pregnant and normal pregnant women.
CHAPTER 2 
REVIEW OF LITERATURE
Introduction
Preeclampsia, with a classic triad of hypertension, proteinuria, and edema, is a 
disease surrounded by mystery. Despite over 100 years of research by thousands of 
investigators, much about the disease is unknown. There is no concrete decision about the 
cause of preeclampsia and there is no “cure” for the disorder when it progresses other 
than delivery of the fetus (Anderson et al 1998).
The literature about preeclampsia is numerous. Throughout the years definitions 
have been added and taken away firom the diagnosis. Many things have changed in the 
medical community’s understanding of the disorder’s diagnosis, risk factors, 
pathogenesis, and treatment. Even the name has changed from toxemia of pregnancy to 
preeclampsia (Anderson et al 1998). There is much more to be discovered about this 
disorder to know how to more quickly diagnose and more properly treat women with 
preeclampsia.
Preeclampsia
Preeclampsia is the most common complication of pregnancy today (Redman 
1992). It relates to an increased risk of perinatal mortality and morbidity. This risk is 
increased for both the mother and the fetus (Cuimingham et al. 1997). It is the most 
important cause of maternal mortality in the western world (Konijnenberg 1997 Feb).
Perfectly healthy women can die o f preeclampsia, and that is why it is of such great 
concern (Redman 1992).
Preeclampsia (also known as toxemia syndrome (Fauci et al 1998, Anderson et al 
1998» usually occurs during the first pregnancy (Fauci et al 1998, Barron et al. 200, 
Lenfant et al.l990. Burrow, Dufly 1999, Cunningham et al. 1997, Redman 1992). This 
condition is unique to pregnancy and only occurs in that setting. It is a multisystem 
disorder that involves hypertension, proteinuria and generalized edema, with additional 
symptoms including coagulation abnormalities, liver function abnormalities (Barron et al 
2000), sodium retention, and/or hyperreflexia (Fauci et al. 1998).
Preeclampsia is believed to originate in the placenta, an organ shared by the 
mother and the baby, which causes the effects to relate to both persons (Redman 1992). 
The pathogenesis and pathophysiology is not known and the theories of such will be 
discussed later.
Two to ten percent o f all pregnancies result in preeclampsia (Barron et al 2000, 
Konijnenberg A et al. 1997 Feb, Burrow, Duffy 1999, Cunningham et al 1997, Redman 
1992, Lenfant et al. 1990, Witlin et al. 1999). As many as 1 in 10 of all pregnancies and 1 
in 5 of first time moms will get preeclampsia to some degree. One in 20 first time moms 
get a serious form of the disease and 1 in 100 first time moms will get a form so serious 
that it threatens the life of the mother or the baby (Redman 1992). The occurrence is seen 
to hit hardest the women on either end of the reproductive age spectrum and is more 
conunon in teenagers or those older than 35 years old (Cunningham et al. 1997).
While preeclampsia is primarily a disease of the first pregnancy, the risk of 
reoccurrence increases for the second and subsequent pregnancies if a woman had
preeclampsia during her first pregnancy (3.4% risk) when compared to women who had a 
normal first pregnancy (Burrow, Duffy 1999). A change in paternity between the first and 
subsequent pregnancies increases the risk up to the level of a first pregnancy all over 
again (Burrow, Duffy 1999, Li, Wi 2000).
Preeclampsia usually occurs at or after the 20* week of pregnancy (Barron et al 
2000, Redman 1992, Lenfant et al. 1990). The foundations for getting preeclampsia are 
believed to be beginning to be set up in the first half of the pregnancy. However the 
symptoms do not occur until the last 3 months of pregnancy (Redman 1992). An early 
detection test, therefore, is a necessary tool and should be utilized to identify the women 
who may develop preeclampsia and try to treat them early before they progress to 
eclampsia. Early identification and treatment could prevent the progression to eclampsia.
Preeclampsia, if it is not controlled, can progress from a mild form to a serious 
form, and even to eclampsia itself. This progression can be slow, and not go beyond mild 
preeclampsia, or can be more rapid, progressing to severe disease in days to weeks. It 
can be fulminant also and progress firom mild to severe to eclampsia in days or even 
hours. This is why it is very important to diagnose preeclampsia correctly and quickly.
The goal of treatment is then to prevent eclampsia fix>m occurring (Lenfant et al. 1990).
Eclampsia is the term for general tonic/clonic convulsions that develop in addition 
to the triad of hypertension, edema, and proteinuria in some women. The convulsions are 
induced by hypertension and/or aggravated by pregnancy. The woman can have 1 or 2 
convulsions to even 100 or more. They can occur before (antepartum), during 
(intrapartum), or after (postpartum) labor. They are more common during the third 
trimester and the risk of developing eclamptic seizures in women with preeclampsia
increases as the woman gets closer to full term (Cunningham et al 1997). The péripartum 
seizures may be due to hypertensive encephalopathy (Barron et al 2000).
Preeclampsia can be pure (the disease alone) or superimposed on chronic 
hypertension. Either way the disease represents a great danger to the fetus and the mother 
(Lenfant et al. 1990). Approximately 50,000 women die each year 6om eclampsia 
worldwide. There is considerably less death in developed countries due to prenatal care. 
Even so, 18% of the 1450 maternal deaths in the United States Grom 1987 to 1990 were 
from complications of pregnancy-induced hypertension (Cunningham et al. 1997). Most 
maternal deaths attributed to preeclampsia occur in the setting o f uncontrolled 
hypertension. Most are related to an ensuing intracerebral hemorrtiage (Burrow, Duffy 
1999).
With such a common and serious disease you would think that everyone knows 
about it and is on the lookout for it. This is not the case however. The general public 
knows much more about rare complications of pregnancy such as Down syndrome and 
spina bifida than they do about the more common problem of preeclampsia (Redman 
1992). The public, and the medicinal community, need to be educated about this disease 
and more research must be done in this arena.
Diagnosis of Preeclampsia
The major signs and symptoms of preeclampsia are hypertension, proteinuria, and 
edema. Other signs and symptoms include hematoconcentration, hypoalbuminemia, 
hepatic function abnormalities, coagulation abnormalities, increased urate levels (Lenfant 
et al 1990), hyperreflexia, visual disturbances, thrombocytopenia (Fauci 1998), and
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others. The diagnosis is often made based on the hypertension, edema, and proteinuria. 
The initial onset, however, is usually seen with the rqxid development of edema and a 
rise in blood pressure (Fauci et al 1998).
Hypertension is the first thing that is looked at to diagnose an individual with 
preeclampsia. Hypertension in pregnancy can be diagnosed using the same methods as it 
is in non-pregnant individuals, using a spiromometer, but the definition of hypertension 
in a pregnant woman is different than a non-pregnant individual. There are also other 
issues involved in diagnosing the hypertension in pregnant women.
If the patient has been followed with normal prenatal care then hypertension can 
be diagnosed in one of two ways. If there is an increase of systolic blood pressure of 30 
mm Hg or more in the late second trimester or third trimester compared to the average 
blood pressure of earlier pregnancy values hypertension can be diagnosed. The second 
way to diagnose hypertension is if the diastolic blood pressure has increased 1S mm Hg 
or more compared to the earlier values. If the patient’s prior blood pressure is not known 
than readings of 140/90 nun Hg or above are considered hypertensive (Lenfant et al 
1990). The earlier pregnancy values are used in the first method because normal blood 
pressure changes with pregnancy. Both systolic and diastolic blood pressure normally 
decrease 10 to 15 mm Hg during pregnancy, therefore a diastolic of >75 during the 
second trimester and > 85 during the third trimester are abnormal (Fauci et al. 1998). This 
means that a woman may be within the normal range (less than 140/90) and still have 
preeclampsia (Lenfant et al 1990).
Another problem in developing a diagnosis of hypertension in order to diagnose 
preeclampsia is that blood pressure measurements fluctuate throughout the day, and fix>m
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minute to minute, in these patients (Lenfant et al. 1990). If repeated measurements over a 
4 to 6 hour time period show the blood pressure to be abnormal, the diagnosis can be 
made. It is important to note also that hypertension in these individuals is more severe at 
night (Fauci et al 1998).
The next step in making the diagnosis is testing for proteinuria. This value varies 
from woman to woman and from hour to hour in the same woman making this a difficult 
test as well. Abnormal values include proteinuria of at least 300mg/24hrs or lOOmg or 
more in the last two specimens taken at least 6 hours apart (Cunningham et al. 1997).
Proteinuria is caused by problems in the renal system. In a normal pregnancy the 
glomerular filtration rate (GFR) o f the kidneys increases by 30 to 50%. With 
preeclampsia the GFR is decreased instead of increased or may stay the same.
Glomerular filtration rate is tested for using serum creatinine and BUN laboratory 
tests. A serum creatinine of greater than 70/unol/L or a BUN of greater than 4.6 nunol/L 
are considered abnormal in pregnancy (Fauci et al 1998).
Proteinuria is a late sign o f preeclampsia. It is minimal or lacking in the early 
and mild stages of the disease and shows up most in the severe forms. Proteinuria almost 
always develops later than hypertension, edema, and weight gain (Cunningham 1997).
Edema is the abnormal accumulation of fluid in the interstitial spaces of tissues 
(Anderson et al 1998). Some edema is a normal complication of pregnancy. However in 
preeclampsia the edema is seen as part of the triad of the disorder. Edema is diagnosed by 
looking for swelling and pitting in the legs, feet, and hands and by looking for abnormal 
weight gain.
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Edema can be measured by looking at weight gain because fluid retention leads to 
weight gain. A sudden increase in weight may precede the development of preeclampsia. 
This may be the first visible sign o f the impending disease. A weight gain of about 1 
pound a week is normal in pregnancy. If the weight gain is greater than 2 pounds a week 
or 6 pounds in a month the diagnosis of preeclampsia must be considered (an the other 
diagnostic factors looked at). This weight gain is due to abnormal fluid retention in the 
preeclamptic patient. A fulminating disease course leading to eclampsia may have 
extreme fluid retention and a weight gain of 10 or more pounds in one week 
(Cunningham et al 1997).
Neurological symptoms that may be associated with preeclampsia include 
hyperreflexia, visual disturbances, and headache. If these neurological signs occur, and 
especially if they are persistent, concern should be raised for the development of 
convulsions (eclampsia) (Fauci et al. 1998). A headache is unusual in milder cases but 
increases in firequency in severe disease. The headaches are often firontal or may be 
occipital. A severe headache almost always precedes the first eclamptic convulsions so 
headaches in preeclamptic patients are very important (Cunningham et al. 1997).
Other signs and symptoms may be associated with the development of 
preeclampsia. One possibility is jaundice or abnormal liver functions. There can also be 
hematological problems such as thrombocytopenia, microangiophilic hemolytic anemia, 
HELLP syndrome (/femolysis, Elevated Eiver function tests. Low Platelets), or 
disseminated intravascular coagulation associated with preeclampsia. Another problem 
that can occur with preeclampsia is fibrin deposits in the kidneys and liver (Fauci et al.
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1998). Epigastric or right upper quadrant pain can also occur. This often a sign o f severe 
preeclampsia and may be indicative of imminent convulsions (Cunningham et al 1997).
There is a test that can be used to help diagnose preeclampsia. It is the roll over 
test. It checks for an increased sensitivity to angiotensin II that is seen with 
preeclampsia. If there is an increase in diastolic blood pressure of 20 mmHg or more 
upon changing the patient’s position ftom that of lying on the side to lying on the back 
the diagnosis can be confirmed (Fauci et al 1998).
Once the diagnosis of preeclampsia has been made by the discovery of these signs 
and symptoms, the severity can be assessed. Mild preeclampsia has a diastolic blood 
pressure of less than 100 mmHg and trace to 1+ proteinuria. Most other signs are absent 
or minimal (Cunningham et al 1997). Ominous signs in preeclampsia include blood 
pressure 160 mmHg or more systolic or 110 mmHg or more diastolic, proteinuria of 
2.0gm or ore in 24 hours, increased serum creatinine, platelet count less than 100,000, 
evidence o f microangiopathic hemolytic anemia, elevated liver enzymes, headache or 
visual disturbances, epigastric pain, retinal hemorrhage or exudate, pq)illedema, or 
pulmonary edema. These signs show multisystem involvement and serious disease 
(Lenfant et al 1990). Despite the staging of severity, all cases of preeclampsia (even mild) 
should be considered potentially dangerous because they can all lead to eclampsia 
(Burrow, Duffy 1999).
Cause/Pathophysiology o f Preeclampsia 
The exact cause of preeclampsia is unknown. Some possible explanations and 
theories have been explored however. These include an immunological basis, genetic
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predisposition, dietary deficiencies, vasoactive compounds, and endothelial dysfunction 
(Cunningham et al. 1997).
Immunological theories for the development of preeclampsia hold that because 
preeclampsia is a condition of the first bom maybe the disease due to the woman not 
having an effective immunization by a previous pregnancy. This would result in a 
woman not developing immunological tolerance to the fetus (Cunningham et al. 1997, Li, 
Wi 2000). This can be seen in a study with women who have changed paternal status 
between two children. If the woman changes her partner, the “protective status” of the 
first child is seen to be “lost”. This is because the new father’s immunological maricers 
are different than the father of the first child and the fetus is seen as a different kind of 
foreign (Li, Wi 20(X)). This immunological theory is also supported since the first 
pregnancy, in which the mother has not been immunized by previous pregnancies, is seen 
to have a larger number o f antigenic sites on the placenta compared to the amount of 
antibody (Cunningham et al 1997).
Genetic predisposition is seen as a possible cause o f preeclampsia. The disorder 
does %q)pear to have some familial tracing. It may be due to a single gene or multifactoral 
polygenetic inheritance (Cunningham et al 1997, Barron et al 2000).
There are possible dietary deficiencies implicated such as calcium and magnesium 
that may lead to preeclampsia. These, however, do not have a whole lot of proof to 
validate their role. However a study has shown that if you increase your calcium intake 
you decrease the risk of preeclampsia. This increased calcium does not adversely effect 
the fetus and may be recommended to patients (Cunningham et al 1997).
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The major pathological feature of preeclampsia is increase in peripheral vascular 
resistance. Vascular resistance to blood flow leads to hypertension (Cunningham et al 
1997). The pathogenesis of this is due to many factors. One of these is exaggerated 
vascular responsiveness to circulating angiotensin n  and catacholamines (Lenfant et al 
1990). It can also be due to increased production of endothelin 1 and serotonin from the 
activated platelets in the microvasculature, which can lead to hypertension (McCrae et al 
1992). Another possible cause is increased vascular reactivity to pressors that is seen in 
preeclamptic patients. Normally pregnant women become refractory to vasopressors, but 
in preeclampsia they are not. In fact quite the opposite happens and they become even 
more reactive to them. These pressors can include norepinephrine, angiotensin II, 
vasopressin, etc. The exact mechanism of this is unknown (Cunningham et al 1997).
Endothelial damage can lead to the activation of endothelium. This promotes 
coagulation and makes the endothelium more sensitive to all o f the vasopressor agents. 
This can be seen in the glomerular capillary endothelium in preeclamptic patients. 
Vasoconstriction leading to hypertension can also be due to vasospasm. These 
vasospasms can occur and damage the vessels. When this endothelial damage occurs the 
platelets come to be deposited in the subendothelium (Cunningham et all 1997).
One possible cause for the begiiming of the pathogenesis of preeclampsia is that 
there is an alteration in the vasculature supply o f blood to the placenta during the time 
when the arterial supply to the placenta is being developed. This may occur as early as 
the beginning of the second trimester. The manifestations of the ischemia due to this are 
not seen until the third trimester though. How these placental vascular abnormalities 
cause systemic disease is not known (Burrow, Duffy 1999, McCrae et al 1992). These
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deficient arteries cause ischemia to the placenta the placenta releases diminished amounts 
of mediates or releases pathological factors. There is an increase in the amount of 
thromboxane and a decrease in the amount of prostacycline produced. This can lead to 
the development of hypertension, increased platelet activation, and reduced 
uteroplacental blood flow all seen in preeclampsia. (McCrae et al 1992).
Consequences of Preeclampsia
Both maternal and fetal consequences must be considered when thinking about 
preeclampsia. Preeclampsia originates in the placenta, an organ shared by the mother and 
the baby, which causes the effects of preeclampsia to relate to both persons (Redman 
1992).
Preeclampsia can lead to two life threatening complications, HELLP syndrome 
and eclampsia. HELLP syndrome (A/emolysis, £levated Liver fimction tests. Low 
Platelets) is an emergency requiring prompt termination o f the pregnancy (Lenfant et al 
1990). HELLP is seen to be a variant of preeclampsia and not necessarily a unique 
disorder in and of itself. Thrombocytopenia is a prominent manifestation of 
H£LLP.(McCrae et al 1992). HELLP is associated with a particularly adverse maternal 
and fetal prognosis (Burrow, Duffy 1999).
The second life threatening condition is eclampsia. This is a convulsive phase. It 
was at one time the major cause o f cerebral bleeding and maternal death associated with 
preeclampsia (Lenfant et al 1990).
Things that can predispose a patient to the development o f lethal complications 
include abrupto placentae, disseminated intravascular coagulation, cerebral hemorriiage.
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hepatic failure, or acute renal failure (Lenfant et al 1990). These can be due to the 
pathophysiology or can be one of the other consequences of the disease.
Endocrine changes can occur during preeclampsia. In normal pregnancy renin, 
angiotensin U and aldosterone are all increased. In preeclamptic pregnancies they are not 
increased (Cunningham et al 1997).
The kidneys can also have changes in a preeclamptic patient. The renal perfusion 
and glomerular filtration rate are decreased in these women. The plasma uric acid 
concentration is increased. There is also proteinuria as has been discussed (Cunningham 
et al 1997).
Hematological changes occur during preeclampsia. There are changes in 
coagulation and platelet aggregation as well as thrombocytopenia. The 
thrombocytopenia can be induce acutely by preeclampsia or eclampsia. It reflects the 
severity of the disease. Overt thrombocytopenia with a platelet count of less than 
100,000 is considered a very ominous sign and the infant should be delivered. Platelet 
aggregation is increased in preeclamptic women. This could be due to the immunological 
processes or due to platelet deposition at the site of endothelial damage (as discussed in 
pathophysiology). Platelets from preeclamptic women have surface alterations and are 
likely to be associated with IgG. Thrombocytopenia and preeclampsia are related to 
prolonged bleeding time (Cunningham et al. 1997).
The cardiovascular system is effected by preeclampsia. There are hemodynamic 
changes associated with preeclampsia, which include vascular resistance, cardiac output, 
left ventricular filling, heart rate, and many more. The blood volume is also seen to be 
effected. In a normal pregnancy the blood volume increase to 5000 mL but a
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preeclamptic or eclamptic patients blood volume is seen to be only 3S00mL. This means 
that they are sensitive to even the normal blood loss at delivery (Cunningham et al. 
1997).
Consequences of preeclampsia that effect the fetus most directly are preterm 
delivery and intrauterine growth retardation. This combination can result in high 
perinatal mortality. The goal o f treatment includes delivery of a healthy baby and the 
health restoration of the mother so these consequences must also be considered (Li, Wi 
2000).
Treatment of Preeclampsia
There is nothing that can be done to “cure” preeclampsia short of delivering the 
fetus (Fauci et al 1998, Cunningham et al 1997, Barron et al 2000, Witlin et al 1999, 
Witlin et al. 2000). Prompt diagnosis, ongoing assessment of maternal and fetal health, 
and timely delivery are the key aspects to be addressed in managing a patient with 
preeclampsia (Barron et al. 2000).
There are really two management options. One is pregnancy prolongation (either 
expectant management or 48 hour delay for corticosteroid benefit) in an attempt to 
improve neonatal outcome. The other is immediate delivery (Witlin et al 2000).
Ending the pregnancy is always in the best interest of the mother, but may or may 
not be in the best interest of the fetus. If the baby is at greater than thirty-six weeks 
gestation it should be delivered because pulmonary maturity should have been achieved 
by this point. However, you must deliver regardless of age if there is evidence of 
advanced disease or impending eclampsia (Barron et al 2000). Other indications for
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immediate delivery include non-reassuring fetal status, vaginal bleeding, eclampsia, 
uncontrolled severe hypertension, pulmonary edema, compromised renal function, 
persistent severe headaches or vision changes, or a platelet count less than 100,000/mm^ 
(Witlin et al 1999).
One primary recommendation is bed rest in a quiet environment (Fauci et al 
1998, Lenfant et al 1990). Bed rest is considered good because is maximizes the 
uteroplacental blood flow, helps reduce premature labor, lowers the blood pressure, and 
promotes diuresis (Lenfant et al 1990). It also helps to buy some time for the baby to 
mature.
Bed rest is often augmented with other treatments. These include control of the 
blood pressure(antihypertensives and decreased sodium intake) and neurological 
manifestations (magnesium sulfate) (Fauci et al 1998).
Blood pressure is controlled with antihypertensives to prolong the pregnancy until 
delivery can safely occur. Antihypertensives that can be used include beta-blockers, 
calcium charmel blockers, vasodilators, and central sympathetic antagonists. Diiuetics are 
avoided (Fauci et al 1998). ACE inhibitors are contraindicated in pregnancy because they 
cause fetal death (Cunningham et al 1997, Fauci et al 1998)
Medications are given prophylactically to prevent eclampsia from occurring. The 
rate of development of eclampsia for a woman with severe preeclampsia is 1% to 7% 
(Szal et al. 1999). The main treatment is with magnesium sulfate. It can be given 
prophylactically to prevent convulsions or as a treatment to stop the seizures when they 
occur. The question is when do you give this drug. For now the recommendations are to 
give it to all women with an established diagnosis of preeclampsia until further studies
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are done (Barton et al. 2000). The risk of seizure development despite standard ther^y  is 
0.3% (Szaletall999).
Prevention o f Preeclampsia
No consistently effective treatment has been found to prevent preeclampsia, 
though many have been tried. Diuretics did not woric. Salt restriction is not effective. 
Antihypertensives woric to help decrease the blood pressure but do not effect the 
pathology of the preeclampsia itself since the primary pathology is not due to the high 
blood pressure. Calciiun has been shown to help prevent the development o f 
preeclampsia and does not hurt the fetus so it can be tried. Magnesium has been tried but 
does not help (Barron et al 2000).
Low dose aspirin seems to be the most promising preventative therq>y attempted 
currently and is used in high-risk individuals. It inhibits platelets and thromboxane 
synthesis to inhibit platelet aggregation and vasoconstriction. It has been seen to reduce 
the incidence of preeclampsia by 9%. But it is not recommended for everyone.. .just high- 
risk individuals (Barron et al 2000).
Early Detection
Pregnant women are usually unaware of the two most important signs of 
preeclampsia, the hypertension and proteinuria. These are not things that people normally 
notice, because they do not produce noticeable symptoms. By the time the symptoms of 
headache, visual disturbance, epigastric pain, etc develop the preeclampsia is in the 
severe stage and delivery is imminent. Also disturbing is the fact that 10% o f eclamptic
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seizures occur before the overt proteinuria can be picked up by current methods, therefore 
before the patient is diagnosed with preeclampsia (Cunningham et al 1997). An early 
diagnostic or predictive test is therefore desperately needed for this disorder.
The first thing done for early detection is to look for risk factors. These include 
nulliparity, changing paternity in successive pregnancies, family history of preeclampsia 
or eclampsia, diabetes, multiple gestation, extremes o f age, high body mass, hydatidiform 
mole, fetal hydrops, chronic hypertension (Barron et al 2000), renal disease, and other 
chronic vascular disease (Cunningham et al 1997). If they are predisposed, as seen in 
women with multiple risk factors, then they need to be observed very carefully. This 
includes checking for rapid weight gain and blood pressure changes every week during 
the last month of pregnancy and every two weeks for the two months preceding the last 
month of pregnancy. Education o f the patient to report any signs and symptoms of 
headache, visual changes, epigastric pain, and edema are also very important 
(Cunningham et al 1997).
Risk factors and careful observation alone are not enough, many times, to predict 
early enough a woman’s chance o f becoming preeclamptic. Another test is needed. 
Numerous pathophysiologic events present in preeclamptic women weeks to months 
before the disorder is clinically recognized with the history, hypertension, and proteinuria 
(Barron et al 2000). Maybe one o f these can become a test for the disease.
A platelet activity test out o f Detroit (Wayne State) showed that abnormal platelet 
activity can be detected as early as the first trimester. Because of this study it may be 
possible to predict preeclampsia and explain why it is modifiable by antiplatelet agents 
(Redman 1992).
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Platelets 
Structure and Function 
Platelets are not cells, but cell disk-shaped cell fragments. They are formed in the 
bone marrow from large cells called megakaryocytes. The outer edges of megakaryocytes 
extend into the lumen of the bone marrow blood sinuses and the extensions fragment into 
the disk-like platelets (McCance, Huether 1998, Silverthom et al 1998).
Platelets are smaller than red blood cells. They have no color to them (Silverthom 
et al 1998). They do not have a nucleus and therefore do not have any DNA. They are 
unable to divide to form new cells (Me Cance, Huether 1998). Platelets do contain many 
intercellular organelles, however, including mitochondria, smooth endoplasmic 
reticulum, and granules. These granules are filled with the clotting proteins and cytokines 
the platelet needs to perform its job in clotting (Silverthom et al 1998).
In an average person there are 140,000 to 340,000 platelets/mm^ circulating in the 
blood. There are also an additional one third of the body’s total amount of available 
platelets that are stored in the spleen most of the time (Me Cance, Huether 1998). While 
the platelets are present in the circulating blood at all times, they are not activated unless 
there has been damage to the walls of the circulatory system. Platelets are involved in 
maintaining hemostasis, “the process of keeping blood within the blood vessels by 
repairing breaks without compromising the fluidity of the blood ” (Silverthom et al 1998). 
They are essential in coagulation and the control of bleeding when injuries occur 
(McCance, Huether 1998).
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In their circulating, non-activated state a number o f glycoproteins are present on 
the surface o f the platelet. These glycoproteins allow chemicals and other substances to 
bind to the cell. The binding to some o f these sites allows messages to be transported to 
the cell through the receptors made by the glycoproteins. Some o f the platelet cell surface 
proteins include glycoprotein ma; glycoprotein 11b; glycoproteins Ha and Ic (Fibronectin 
Receptor); glycoproteins 11a and la (Collagen Receptor) glycoproteins lb a , lb A DC, and 
V (Von Willebrand Factor Receptor); glycoproteins 11a and Ic (Laminin Receptor); and 
glycoprotein mb ou IV (Thrombospondin Receptor) (Immunotech International).
Platelets also contain two types of granules. The first type of granule is the alpha 
granule. This granule has the adhesion molecule P-selectin on its membrane surface and 
contains many of the molecules used in coagulation and the coagulation cascade. These 
include fibrinogen, fibronectin, factors V and Vm, platelet factor 4, platelet derived 
growth factor, and transforming growth factor The second type of granule is the dense 
body or delta granule. This granule contains adenine nucleotides (ADP and APT for 
engery), ionized calcium, histamine, serotonin, and epinephrine (Kumar et al 1997).
When there is a vascular injury the initial hemostasis occurs by blocking the hole 
with a platelet plug (Silverthom et al 1998). When vascular injury occurs the endothelial 
extracellular matrix is exposed. This leads to exposure of collagen, proteoglycans, 
fibronetin, and other adhesive glycoproteins. When the platelet comes in contact with 
these substances it becomes activated and undergoes three main reactions: adhesion and 
shape change, secretion of granule contents, and aggregation. The platelets adhere to the 
damaged vessel’s endothelial extracellular matrix with interaction with Von Willebrand’s 
factor. The released granules are used both to stimulate and to be used in the coagulation
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cascade and in mediating aggregation. In aggregation the platelets adhere to one another 
forming a platelet plug using vasoconstrictor thromboxane A% (TXAz), which the platelet 
secretes when it is activated, and ADP, which is released fiom the delta granule. Also at 
this time the platelet is activated. This activation leads to the expression of a phospholipid 
comples that becomes a binding site for calcium and coagulation factors needed in the 
intrinsic clotting pathway. The coagulation cascade, activated by the platelets and the 
injured cells, produces thrombin, which binds to and reinforces the platelet plug (Kumar 
et al 1997).
When platelets are activated their surface proteins change also. The glycoproteins 
present on an activated platelet include sites for the binding of GMP 140 and 
glycoprotein S3. The other glycoproteins on the surface of the platelet form receptors are 
bound to their respective molecules in activation (Immunotech International).
Platelets and Preeclampsia
Platelets are associated with vasospasms, occlusive vascular lesions, in numerous 
organ systems including the placenta. They are also known to activate the coagulation 
system. Evidence for the involvement o f circulating platelets in preeclampsia is in the 
decreased platelet count, change in platelet aggregability, and high levels of platelet 
specific protein B-thromboglobulin that have been noted in preeclamptic patients. 
Explanations for increased platelet activation are an intrinsic change in platelet 
responsiveness or increased consumption/turnover in the microvasculature secondary to 
hypertensive vasospasm (Socol et al 1985). Whatever the cause this could be our chance 
at a predictive test.
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Platelets play a substantial role in the pathogenesis o f preeclampsia. Platelets may 
he activated hy damaged endothelium in systemic or placental circulation during 
preeclampsia. Despite where the damaged endothelial extracellular matrix is exposed the 
result is the same, activation of platelets.
Activated platelets have different exposure of glycoproteins and glycoproteins 
complexes on their surfaces compared with non activated platelets. Flow cytometry can 
detect the activated platelets in circulation. This has been done hy Janes and Goodall. 
They discovered a significant increase in the platelet surface expression of CD 63 in 
preeclamptic patients (Konijnenherg et al 1997 Feh).
Thrombocytopenia and Preeclampsia 
Thrombocytopenia is a reduction in the number of platelets. It is the most 
common cause of bleeding disorders (Anderson et al 1998). “Between IS and 50% of 
patients with preeclampsia develop thrombocytopenia at some point in the course of their 
illness making preeclampsia a common cause of significant thrombocytopenia during the 
third trimester of pregnancy” (McCrae et al.1992).
The thrombocytopenia can lead to bleeding problems in delivery. Major bleeding 
is rare, but minor bleeding is common as well as post-operative oozing after cesarean 
section. This bleeding may result firom the effects of a coagulopathy involved with the 
preeclampsia. Treatment is replacing the lost platelets with donor platelets, but it may 
not help if the preeclampsia is causing platelet destruction (McCrae et al. 1992).
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Flow Cvtometrv
The FACScan flow cytometer is a multiparameter instrument with up to three 
fluorescence and two scatter measurements for each cell (Coon et al 1987). The 
fluorescence is measured based on the number of antibodies with fluorescent maricers that 
are attached to the antigens on the cell surface (Leytin et al 2000). The forward and side 
scatter measurements determine the type of cell, separating platelets, erythrocytes, and 
white blood cells based on size (Shattil et al1987). Many o f the adjustments, to settings 
of the optical alignment and laser power, are under software control making it an easy 
instrument to woric with. (Coon et al 1987)
Flow cytometry is commonly performed in a flow laboratory. The flow cytometer 
is compatible with IBM computers. This allows the data to be transferred to any IBM 
compatible computer and then analyzed off site as well as on site (Coon et al 1987). The 
software used in this study is the Cellquest software system.
Detection of Platelets and Platelet Activation 
The first step to flow cytometric analysis of platelets is the differentiation of 
platelets fiom other cells in the whole blood sample. The platelets need to be 
differentiated fiom erythrocytes and white blood cells. This can be done by the flow 
cytometer using the light scatter profile. On the forward and side scatter profiles the 
platelets can be clearly separated fiom the larger erythrocytes and white blood cells. This 
scatter is not affected by the presence of platelet agonists. For platelet analysis a gate is 
set around the scatter area thought to be platelets. Then this area, containing mostly
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platelets with approximately 5% erythrocytes, can be assessed for the following surface 
glycoproteins (Shattil et al 1987).
Platelets and platelet activation are detected with the help of monoclonal 
antibodies to the glycoproteins on the cell surface. Monoclonal antibodies have been 
discovered which recognize cell surface differentiation antigens. These monoclonal 
antibodies were studied to determine what antigens they were reactive to. Then they were 
grouped according to the reactivities on specific target cells. Cluster analysis was used to 
define groups of antibodies that were statistically similar and these clusters were termed 
clusters o f differentiation (CD) (Coon et al 1987).
CD 41 is a monoclonal antibody that binds to glycoprotein Hb on the surface of a 
resting platelet. CD 61 is a monoclonal antibody that binds to glycoprotein Ola, which is 
also present on the surface of a resting platelet. The presence of these glycoproteins, 
identified by the monoclonal antibody markers confirms that these cells are indeed the 
platelets that we wish to analyze (Inununotech International)
CD62 is a monoclonal antibody that binds to GMP-140, a protein from the alpha 
granule o f the platelet that is expressed on the surface of the platelet after activation 
(Leytin et al 2000). Since the alpha granule only releases it’s contents after activation of 
the platelet this is a good maricer to look for when attempting to identify activated 
platelets.
PAC-1 is an IgM antibody that binds to the activated form of the glycoprotein 
nb/nia complex. This complex is only present after activation of the platelet (Shattil et al 
1987). Therefore it is an excellent maricer to use when looking for activated platelets.
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In order to determine platelet activation two parameters are looked at when using 
CD 62, these are the percentage of CD62 positive platelets in the total platelet population 
and the mean fluorescence of the CD62 positive cells, which is expressed as mean 
channel fluorescence. The percentage o f CD62 positive platelets tells us the proportion 
o f activated cells in the total platelet population. This gives us a quantitative idea o f how 
many activated cells are present in the total platelet population. The mean fluorescence 
gives us an idea of the quality o f the activation of the platelets. It is based on density of 
the CD 62 molecules present in the sample (Leytin et al 2000). This tells us how strongly 
the platelets are reacting to the antibody.
Similar Studies
Two studies have been performed in the Netherlands that are similar to this study 
being performed here.
In February of 1997 Konijnenberg et al released a study that investigated, via flow 
cytometry, to what extent platelets circulate in an activated state during normal 
pregnancy. They then looked to see what extent platelets circulate in an activated state 
during a preeclamptic pregnancy. It was seen (comparing 10 preeclamptic with 10 
normotensive pregnant women in the third trimester) that there is enhanced platelet 
aggragation in some normal pregnant women (4) and in all of the preeclamptic women 
(10). This was discovered using numerous platelet maricers. It was also found in this 
study that platelet count and mean platelet volume did not differ significantly, but the 
activated platelets were significantly higher in preeclamptic patients. An obvious
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downfall o f this study is the small numbers, but as a pilot study almost to ours it is very 
useful.
Another study, done by Konijnenberg et al in August o f 1997 took this a step 
further. They checked the blood o f244 patients at the first, second, and third trimester 
and after delivery for the surface antigens antiCD62P, antiCD63, and antiCD31. It was 
discovered that anti CD63 was the only one that worked to predict preeclampsia and that 
it could do so at 13 weeks gestation. Therefore increased first trimester CD63 is an 
independent risk factor for development o f preeclampsia. This increased activation of the 
platelet was seen on average 21 weeks (with a range of 3 to 27) before the onset of the 
clinical signs and symptoms of preeclampsia would be seen. This opens a new 
perspective for early identification and clinical intervention in these people. This study 
was intended to show the use of combining both the platelet activation test with initial 
blood pressure measurements as a tool to identify those at high risk for developing 
preeclampsia and to get intervention to those that need it. It was suggested to possibly use 
aspirin therapy on these individuals.
Implications of This Studv 
The implications of this study can be obviously seen. Preeclampsia is a serious 
disorder with serious consequences to the mother and the fetus. Eclampsia can be 
prevented and preeclampsia can be treated (to a point) if it is picked up early enough. 
Currently there are no early tests available to help find the women that are at high risk for 
this disease. If platelet markers turn out to be truly predictive women at high risk of 
developing preeclampsia can be identified earlier in the development of the disorder and
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monitored more closely. The protective factors that have been discovered and are 
currently in use (aspirin and calcium) can be used in these women to try to prevent the 
development o f preeclampsia.
At the same time, there is currently no way of predicting which women with 
preeclampsia will progress on to bleeding problems during delivery. If platelet activation 
is identified early in a pregnancy with a high number of the cells being activated, and 
therefore commonly used up prior to delivery, there could be a way to predict bleeding 
complications and possibly treat these women with platelet transfusions to prevent the 
bleeding problems. At the very lease the medical staff would be better prepared for the 
chance of extreme bleeding at the time of delivery.
31
CHAPTERS 
MATERIALS AND METHODS
Studv Design
This study is a cross sectional study looking at the platelet surface glycoproteins 
for activation in preeclamptic pregnant women. The sample population was obtained 
through West Michigan OB/GYN and Spectrum Health. Consent for this study was 
obtained from Spectrum Health Research and Human Rights Comittee by way of 
approval of the research proposal (Appendix A).
The independent variable in this study is the preeclamptic females. The dependent 
variables are the platelet number, mean volume, and the activation status o f the platelets, 
measured by flow cytometric analysis o f the platelet surface glycoproteins.
Studv Site and Subjects
The sample population consisted of non pregnant, normal pregnant, and 
preeclamptic pregnant females. Preeclamptic pregnant females were defined as women 
with pregnancy induced hypertension. The population used for this study was obtained 
firom Dr. Russel Jelesma, M.D. at West Michigan OB/GYN. These women were chosen 
because pregnancy induced hypertension puts a woman at risk of developing eclampsia.
Demographic information on each of the subjects was obtained by Dr. Theresa 
Bacon-Baguley (thesis chair) via the patient’s records. Inclusion criteria for placement in 
the study group of preeclamptic females were women with pregnancy induced
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hypertension. Exclusion criteria for this group were females who had preexisting 
hypertension.
Equipment and Instruments 
The laboratory analysis was performed at the Spectrum Health Flow Cytometry 
laboratory. A Sysmex K-1000 (Coulter Co.) was used to perform the complete blood 
count. A Becton -Dickson FACSort flow cytometer (Becton-Dickson 
hnmunocytometery Systems, San Jose, CA) equipped with Cellquest software was used 
for the analysis o f the platelets.
Antibodies specific for platelets were used to marie the cells as platelets. These 
antibodies wee specific for the GPIIb binding site on the platelets. In this study the 
antibodies used for this purpose were CD 41 (FITC, F7088, DAKO, Denmark) and CD 
41 (PE, R70S8, DAKO, Denmark). Specific antibodies were used for the identification 
of activated platelets. These bound to the GMP-140 site. The antibody used in this study 
to identify activated platelets was CD62 (PE, 348107). These antibodies were tagged to 
be read by the flow cytometer with the presence of two colored labels, FLl-FITC (green) 
and FL2-PE (red).
Procedure 
Platelet (Blood) collection 
After the selection process described above was completed, two 5ml EDTA tubes 
of blood were collected from each subject in the sample population using venipuncture 
with a 21-gauge needle or larger. The first 5 ml EDTA tube of blood, when available.
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was used to run a complete blood count (CBC). It was then discarded in case of thrombin 
formation. Then lOO^ tl of blood fiom the second S ml EDTA tube was fixed with 1 ml of 
1% formaldehyde solution (at 2-8*C) to prevent non specific activation of the platelets. 
This blood was then used for flow cytometric analysis. The blood was fixed within 30 
minutes o f collection to prevent activation.
Platelet Size and Mean Platelet Volume 
In order to obtain a platelet count and mean platelet volume a complete blood 
count was performed using a Sysmex K-1000. As stated previously, the first S ml EDTA 
tube of blood collected, when available, was used for this procedure. This blood was not 
prepared in any special fashion.
Preparation of Platelets for Flow Cytometric Analysis 
The 100 pi of blood that was fixed with the 1 ml of 1% formaldehyde was 
incubated for thirty minutes to ensure that fixing occurred. Next, the blood was 
centrifuged at 2500 RPM for S minutes (at 20-25° C). The supernatant was then aspirated 
and the pelleted blood was resuspended in 2 ml of PBS with 0.1% of sodium azide and 
vortexed. Centrifuging at 2500 RPM for 5 minutes (at 20-25° C) was repeated and the 
supernatant aspirated. The pellet was then resuspended in 1 ml PBS with fetal calf serum 
and 0.1% sodium azide. The blood was then ready to be incubated with the monoclonal 
antibodies.
Each antibody is directly conjugated to one o f two fluorescent fluorochrome 
labels called Flourescein Isothiocynate (FITC) or R-Phycoerythrin (PE). When bound to
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the cell, these labels emit colored fluorescence and can be detected by the flow 
cytometer. Following the above fixing and washing, SO pi of the resuspended blood was 
incubated with 20 pi o f mouse monoclonal antibodies used for controls or commercially 
available antibodies specific for:
- GP nb (CD 41, FTTC, F7088, DAKO, Denmark),
- GP nb (CD 41, PE, R7058, DAKO, Denmark),
- GMP-140 (CD62, PE, 348107, Becton/Dickson, San Jose, CA) and
- Activated Db/lHa (PAC-1, FITC, 340507, Becton/Dickson, San Jose, 
CA).
The blood and antibodies were vortexed, and incubated in the dark for 15-20 
minutes. Following this period, 2 ml of PBS with 0.1% sodium azide was added to wash 
and the solution vortexed. This was now centrifuged at 2500 RPM for 5 minutes (at 20- 
25** C) and the supernatant aspirated. Finally, the pellet was resuspended in 1 ml PBS 
with 0.1% sodium azide and was now ready for flow cytometric analysis.
Flow Cytometric Analysis 
A Becton-Dickson FACSort flow cytometer (Becton-Dickson Immunocytometry 
Systems, San Jose, CA) equipped with Cellquest software was used for the analysis of the 
platelets. Calbrite beads (Becton-Dickson) established fluorescent compensation.
Platelets were distinguished from erythrocytes and white blood cells on the basis of their 
forward scatter and side scatter profiles. The flow cytometer provides information on 
relative size o f a cell (forward scatter of laser light-FSC) and the granularity and
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complexity of a cell (side scatter of the laser light -  SSC). These are compared to known 
values for platelets and the area of platelets is identified. The flow cytometer also 
provides information on the fluorescence intensity o f the two colored labels used (FLl- 
FITC and FL2-PE). The cells passed through the laser beam at a rate o f 1000 cells per 
second. Using the forward scatter and side scatter, electronic gates were established to 
include only platelets and exclude debris. The software was set in acquisition mode and 
the following parameters set to obtain optimal data:
- FSC and SSC were collected on a log scale.
- FACSort detectors were set to: FSC (EOO), SSC (322), FLl (749), FL2 
(690).
Compensation was set at 1.8% for FLl, 14.9% for FL2, and 0% for the other 
detectors, which were not in use. Compensation threshold was set according to the FSC- 
Height and was set at 112. The machine was selected to collect results from 10,000 cells 
in either the medium or high collection modes. The results consisted of scatter plots of 
the cells and histograms of the amounts of fluorescence emitted per cell. Every sample 
nm was saved and analyzed later.
Data Analysis
After each sample had been nm through the flow cytometer, the data obtained was 
printed out and analyzed. An example of an analysis is provided in Figine 1. The diagram 
in the upper left hand comer shows a dot plot on a log vs. log scale o f forward scatter vs. 
side scatter of the total cells collected (10,000). A gate aroimd just the platelets was then 
created based on how the cells scattered and the known sizes and granularity o f platelets.
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Next to the FSC vs. SSC dot plot is another plot o f FLl (Fluorescence 1) for FTTC vs. 
FL2 (Fluorescence 2) for PE. This data was plotted on a log vs. log scale and quadrants 
were set at 10’ on both the FLl and FL2. The quadrants were set to separate Ab bound 
platelets in the data analysis. Below the two dot plots are histograms of each o f the FLl 
and FL2. The statistics for each histogram give the peak and mean channels for each 
antibody (the fluorescence intensity). Since each Ab binds a specific platelet 
glycoprotein, the peak and mean values o f Ab bound represents the peak and mean values 
o f the platelet glycoprotein expressed. The values obtained via flow cytometry are for 
CD 41- FITC (nb), CD 41- PE (flb), CD 62- PE (GMP-140), and PAC-1- FITC 
(activated nb/IUa).
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Figure 1: Example of Flow Cytometry Results. Upper left diagram shows all of 
the cells with the area thought to be platelets (accorcting to size) gated (circled). 
These are the cells analyzed in the rest of the diagrams. The upper right diagram 
has CD 41 (platelet marker) on the horizontal axis and CD 62 (activation marker) 
on the vertical axis. Cells to the right are platelets. Cells higher have more 
activation madcer on them. The bottom two grs^hs show spikes in fluorescence 
for CD 41 (left) and CD 62 (right).
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CHAPTER 4 
RESULTS/DATA ANALYSIS
Technique o f Data Analysis 
Data was analyzed using the computer program SPSS to run statistical analysis. 
The raw data for age, prior pregnancies, number o f live births, gestational age, platelet 
count, mean platelet volume, CD 41 peak, CD 41 mean, CD 41 with CD 62 peak, CD 41 
with CD 62 mean, CD 62%, CD 62 peak, CD62 mean, PAC1%, PACl peak and PACl 
mean were all entered into the program for analysis.
An independent t-test was run on the values comparing the non pregnant to the 
normal pregnant, the non-pregnant to the preeclamptic, and the normal pregnant to the 
preeclamptic. The values were looked at independent of each other so that individual 
changes could be seen in the different groups.
The mean for each variable was assessed to look at the numbers as a whole. The 
standard deviation was also given for each variable for each group to assess the 
variablility within the group as well as between the groups.
The values were assessed initially for equal variances using the Levene’s Test for 
Equality of Variances. If the significance o f the variances was greater than 0.05, equal 
variance was assumed. When this was the case the initial set o f values, in the equal 
variances assumed row, were used for results and analysis. If the significance of the 
variances was less than 0.05, equal variance could not be assumed and the values in the 
second row, equal variances not assumed, were used for results and analysis.
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Next the t-test for equality o f means was looked at. The variables were examined 
to see if  they were statistically significantly different. Since the program runs the 
significance two tailed each o f these numbers were divided by 2 in order to get the one 
sided p-values to look at the statistical significance. Variables with p-values less than 
0.05 are not equal and are thus statistically significant results.
Characteristics of Subjects 
A total o f 50 subjects were analyzed for this study. Twenty- two of them were 
non-pregnant females used as controls, eighteen were normal pregnant females, and six 
were preeclamptic patients. Four of the subjects were excluded due to other 
circumstances including spontaneous abortion, hysterectomy in control population, etc.
The average age of the non-pregnant females was 27.7. The average age of the 
normal pregnant females was 29.4. The average age of the preeclamptic females was 
29.5. None of the age differences between groups showed any statistically significance 
(Table I). This was evident by a p value >0.1 for all three comparisons. There was also 
no statistical significance between the number of prior pregnancies or number of live 
births between the three groups (Table 1).
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Table 1: Characteristics of Subjects
Non-Pregnant
(u=22)
Normal Pregnant 
(n=18)
Preeclamptic
(n=6)
Mean Age 27.6818 29.4444 29.5000
Mean Number of Prior 
Pregnancies
1.1364 1.7778 1.5000
Mean Number of Live 
Births
0.8182 1.2778 0.8333
Results o f Platelet Counts and Platelet Volume 
Platelet counts between the three groups were not statistically significant. The 
mean platelet count for non-pregnant females was 226,000 +/- 57.0. The mean platelet 
count for normal pregnant females was 235,000 +/- 45.7. The mean platelet count for the 
preeclamptic females was 254,833 +/- 54.7 (Table 2). This was not statistically 
significant with p>0.1 in comparisons between all of the groups (Table 3). This means 
that the groups had comparable total number of platelets. No one group had significantly 
more or less number of platelets.
Table 2: Platelet Counts
Non Pregnant 
(0=22)
Normal Pregnant 
(0=18)
Preeclamptic
(0=6)
Mean Platelet Count 
(Standard Deviation)
226,0000 
(+/- 56.9987)
235,000 
(+/.) 45.7088
254,000 
(+/-) 54.6897
Table 3: Sigmiflcauce of Platelet Counts
Non Pregnant vs. 
Normal Pregnant
Non Pregnant vs. 
Preeclamptic
Normal Pregnant 
vs. Preeclamptic
P-valne 0.2955 0.1395 0.1945
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The mean platelet volumes (MPV) were compared between the groups. There 
were no statistically significant dififerences seen in the mean platelet volumes between 
these groups. The mean platelet volume for the non-pregnant group was 9.66 (+/- 0.77). 
The mean platelet volume for the normal pregnant group was 9.70 (+/- 0.73). The mean 
platelet volume for the preeclamptic group was 9.62 (+/- 0.78) (Table 4). This means that 
the size of the platelets was comparable between the groups and there were no major 
differences in platelet size (Table 5).
Table 4: Mean Platelet Volume
Non Pregnant 
(n=22)
Normal Pregnant 
(n=18)
Preeclamptic
(n=6)
Mean Platelet Volume 
(Standard Deviation)
9.6591 
(+/- 0.7725)
9.7000 
(+/- 0.7340)
9.6167 
(+/- 0.7808)
Table 5: Significance of Mean Platelet Volume
Non Pregnant vs. 
Normal Pregnant
Non Pregnant vs. 
Preeclamptic
Normal Pregnant 
vs. Preeclamptic
P-valne 0.433 0.453 0.4075
Results of CD 41
The peak and mean o f CD 41 is analyzed next. This is the maricer for platelets. 
The flow cytometric results for a non-pregnant patient are seen in Figure 2. The platelets 
with CD 41 present are to the right on the horizontal axis (CD41). These results are 
recorded by the flow cytometer as number values for peak and mean fluorescence, which 
were then analyzed and compared.
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Figure 2: Flow cytometry results of CD 41 in Non-Pregnant (Control) Subjects. 
The first diagram (A) shows the forward scatter. Cells that are platelets are 
moved to the right along the vertical axis as they show more concentration of 
fluorescence. The second diagram (B) shows the peaking o f cells with increased 
fluorescence.
The peak values o f CD 41 for non-pregnant subjects were 781.1 (+/-134.4), for 
normal pregnant subjects were 1300.9 (+/- 1642.2), and for preeclamptic subjects were 
761.2 (+/- 206.5). The mean values for CD 41 in non-pregnant patients were 787.1 (+/- 
64.4), in normal pregnant patients were 994.3 (+/- 279.8), and in preeclamptic patients 
were 762.2 (+/- 211.5)(table 6).
Table 6: Mean and Peak of CD 41
Non Pregnant
(n=22)
Normal Pregnant 
(n=18)
Preeclamptic
(n=6)
Mean CD 41 
(Standard Deviation)
787.0909 
(+/- 64.4367)
994.3333 
(+/-279.7661)
762.1667 
(+/-211.4989)
Peak CD 41 
(Standard Deviation)
781.1364 
(+/-134.4461)
1300.9444 
(+/-1642.2194)
761.1667 
(+/- 206.4920)
The dififerences between non-pregnant and normal pregnant as well as normal 
pregnant and preeclamptic in the mean amount of CD 41 seen were statistically 
significant (Table 7). However there was no statistical significance in the values for
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preeclamptic compared to non-pregnant individuals. This shows that there are more 
platelets showing fluorescence in normal pregnancy than in non-pregnant and 
preeclamptic. The preeclamptic pregnant patients have mean CD 41 values that decrease 
flom the normal pregnancy state to lower than the non-pregnant state (Figure 2).
Table 7: Significance of Mean and Peak CD 41
Non Pregnant vs. 
Normal Pregnant
Non Pregnant vs. 
Preeclamptic
Normal Pregnant 
vs. Preeclamptic
Mean CD 41 
P-value
0.003 0.393 0.0385
Peak CD 41 
P-value
0.099 0.415 0.2185
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Figure 3: The mean fluorescence o f platelets containing CD 41 is significantly 
different between non-pregnant and normal pregnant and between normal 
pregnant and preeclamptic. However there is no significant difference between 
the non-pregnant and preeclamptic groups.
Results o f CD 62
In analysis o f the CD 62 marker it is seen that the presence of circulating 
activated platelet membrane proteins was different between the various groups. This 
means that there is difference in activation between these groups.
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Figure 4 shows the flow cytometry readouts for the non-pregnant subjects. The 
platelets are present (peak to the right on the horizontal axis (CD 41) o f A) but not 
activated (not high on the vertical axis (CD 62) o f A. Also not showing much activation 
on the horizontal axis (CD 62) of B.
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Figure 4: The flow cytometry CD 62 for non-pregnant subjects. (A) Platelets are 
identified with CD 41. The cells that have CD 41 bound to them are to the right 
on the horizontal axis. Activation is identified on the vertical axis. (B) The peaks 
of activation are highlighted. There is not much activation.
Figure 5 shows the flow cytometry information fi'om the normal pregnant 
subjects. This sample shows that the majority of the cells are platelets (to the right on the 
horizontal axis, CD41) and many of those platelet cells are activated (high on the vertical 
axis, CD 62). This shows pregnancy to be a hypercoaguable state with activated platelets 
looking to release their contents, bind to each other, and form a platelet aggregate.
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Figure 5: Flow cytometry CD 62 information for nonnal pregnant women. The 
cells are noted to be mostly platelets (to the right on the horizontal (CD41) axis. 
Many of the cells are activated as is seen by their vertical rise on the vertical axis 
(CD 62).
Preeclamptic subjects are shown in figure 6. The platelets show an interesting 
finding in that there are two spikes of platelets seen as well as an area that is the same 
size as the platelets (fell within the gated area to be analyzed) that did bind the CD 41, 
which mariced the cells as platelets.
Another interesting finding in the preeclamptic group is the variation in the 
subjects. These two samples both show the two spikes but one shows a large number and 
percentage of the cells to be activated, while the other patient has very few activated 
platelet cells.
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Figure 6: Flow cytometry data &om preeclamptic subjects. These readouts are 
from two different subjects in the preeclamptic group. Both subjects have an 
interesting finding of two spikes o f platelets along the horizontal (CD41) axis as 
well as cells that fell in the gated area to be analyzed but do not appear to be 
platelets (do not have CD 41 on them). Also the two patients have different 
amounts of activated platelets with the top patient having quite a few activated 
platelets (higher on vertical axis, CD 62) while the bottom patient has a smaller 
number and smaller percent of the total cells activated.
The mean amount of CD 62 present on the platelets of the non-pregnant
population was 40.2 (+/- 72.8). The mean CD 62 present in normal pregnancy was 75.5
(+/- 54.4). The preeclamptic group was similar to the normal pregnancy group with a
mean CD 62 of 70.2 (+/- 21.2). The peak amount of CD 62 was 16.6 (+/- 15.4) for the
non-pregnant subjects, 21.1 (+/- 9.7) for the normal pregnant subjects and 37.0 (+/- 26.8)
for the preeclamptic subjects (Table 8).
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Table 8: Mean and Peak of CD 62
Non Pregnant 
(n=22)
Normal Pregnant 
(n=!8)
Preeclamptic
(n=6)
Mean CD 62 
(Standard Deviation)
40.2000 
(+/- 72.8333)
75.5294 
(+/- 54.4221)
70.1667 
(+/-21.2360)
Peak CD 62 
(Standard Deviation)
16.6000 
(+/- 15.3705)
21.1176 
(+/-9.7396)
37.0000 
(+/- 26.8403)
No statistically significant differences are seen in either the mean CD 62 presence 
or in the peak of CD 62 found amongst any of the groups. However the p-values are very 
close to statistically significant. The p-value between non-pregnant and normal pregnant 
for mean CD 62 is 0.0545, nearly statistically significant. At the same time the p-value 
between non-pregnant and preeclamptic for peak CD 62 is 0.063, also close to being 
statistically significant (Table 9).
Table 9: Significance of Mean and Peak CD 62
Non Pregnant vs. 
Normal Pregnant
Non Pregnant vs. 
Preeclamptic
Normal Pregnant 
vs. Preeclamptic
Mean CD 62 
P-valne
0.0545 0.168 0.4095
Peak CD 62 
P-value
0.1515 0.063 0.1055
Looking at the numbers and graphing them out this near statistical significance is 
even more evident. Figure 7 shows bar grt^hs for mean CD 62 and peak CD 62 values 
between the non-pregnant, normal pregnant, and preeclamptic groups. The peak CD62 
values show a difference between the non-pregnant and the preeclamptic as well as 
between the normal pregnant and the preeclamptic groups. This is not a statistically 
significant difference. The mean CD 62 values ^pear to show a difference between the
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non-pregnant and both the normal pregnant and preeclamptic groups. Again, this was not 
statistically significant
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Figure 7: The peak CD62 values are shown in the top bar graph. A difference is 
seen between the non-pregnant and the preeclamptic as well as between the 
normal pregnant and the preeclamptic groups. TÛs is not a statistically significant 
difference. The mean CD 62 values for the three groups are shown in the bottom 
graph. A difference is seen between the non-pregnant and both the normal 
pregnant and preeclamptic groups. Again, this was not statistically significant.
Another aspect o f the CD62 marker that was analyzed was the percent o f platelets 
that were activated. This looked at the total number of platelets present and the percent of 
those platelets that were activated. The mean percent of activated platelets (marked by the 
presence of CD62) in the non-pregnant subjects was 0.71% (+/- .67). In the normal 
pregnant women the mean percent o f platelets that were activated rose to 20.28% (+/-
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17.59). The preeclamptic subjects had a mean percent of activated platelets 23.17% (+/- 
10.68) (Table 10).
Table 10: Percent of Platelets Expressing CD 62
Non Pregnant
(n=22)
Normal Pregnant 
(n=18)
Preeclamptic
(n=6)
Percent of Platelets 
Expressing CD 62 
(Standard Deviation)
0.7064% 
(+/- 0.6715)
20.28% 
(+/-17.5921)
23.1667% 
(+/-10.6849)
There is a statistically significant difference between the percent of cells 
expressing CD 62 in non-pregnant and preeclamptic women (p-value 0.000). There is 
also statistical significance between the non-pregnant women and the preeclamptic 
subjects (p-value 0.002). There is not statistically significance between the normal 
pregnant and preeclamptic subjects (p-value 0.355) (Table 11). However in looking at 
the raw data 5 out of the 6 preeclamptic women had greater than 25% of their platelets 
activated which is significant when looking at the raw numbers of the other groups. The 
difference in means is seen when the values are graphed out (Figure 8).
Table 11: Significance of Percent of Platelets Expressing CD 62
Non Pregnant vs. 
Normal Pregnant
Non Pregnant vs. 
Preeclamptic
Normal Pregnant 
vs. Preeclamptic
Percent CD 62 
P-value
0.000 0.004 0.355
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Figure 8: The percent of platelets in each group with the CD 62 marker showing 
activation. Not many of the platelets present in the non-pregnant group are 
activated. However, 20% of the platelets in the normal pregnant sample are 
activated and 23% of the platelets in the preeclamptic group are activated.
Results of PAC 1
When looking at the PAC-1 values it is seen that none of the groups are 
statistically significantly different in the expression o f PAC-1. The percent of platelets 
expressing the PAC-1 site for non-pregnant subjects was 0.47% (+/- 0.58). The percent 
of normal pregnant women in the study with the PAC-1 binding site was 0.33% (+/- 
0.47). The percent PAC-1 on preeclamptic patients was 24.33% (+/- 32.65) (Table 12).
Table 12: Percent of Platelets Expressing PAC-1
Non Pregnant
(n=22)
Normal Pregnant 
(n=18)
Preeclamptic
(n=6)
Percent of Platelets 
Expressing PAC-1 
(Standard Deviation)
0.4745 
(+/-0.5841)
0.3300 
(+/. 0.4658)
24.3333 
(+/-32.6548)
The peak and mean PAC-1 values also do not show any statistically significant 
differences between groups. The non-pregnant mean PAC-1 is 787.8 (+/-1665.6) and the 
peak PAC-1 is 673.4 (+/- 169.9). The normal pregnant mean PAC-1 is 1890.5 (+/-
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2251.0) and peak PAC-1 is 1386.1 (+/- 2302.6). The preeclamptic mean PAC-1 is 137.0 
(+/- 75.0) and the peak PAC-1 is 22.0 (+/- 5.2) (Tahle 13). The p-values show that there 
is no statistical significance between the groups in their PAC-1 expression (Table 14).
Table 13: Mean and Peak of PAC-1
Non Pregnant
(n=22)
Normal Pregnant 
(n=18)
Preeclamptic
(n=6)
Mean PAC-1 
(Standard Deviation)
787.8235 
(+/-1665.5745)
1890.5000 
(+/- 2250.9941)
137.000 
(+/- 75.0267)
Peak PAC-1 
(Standard Deviation)
673.4118
(+/-169.8528)
1386.1000 
(+/-2302.5516)
22.0000 
(+/- 5.1962)
Table 14: Significance of Mean and Peak PAC-1
Non Pregnant vs. 
Normal Pregnant
Non Pregnant vs. 
Preeclamptic
Normal Pregnant 
vs. Preeclamptic
Mean PAC-1 
P-vaiue
0.157 0.517 0.218
Peak PAC-1 
P-value
0.365 0.524 0.341
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CHAPTERS 
DISCUSSION AND IMPLICATION
Discussion of Findings
This study has attempted to show an increase in platelet activation in preeclamptic 
women that can be used as an early detection test for women who will develop 
preeclampsia. It also attempted to show that women with increased activation will have 
an increased percentage of activated platelets. The activation of platelets was determined 
by the presence of CD62 and PAC-1.
In looking at the data it is important to remember that the preeclamptic women are 
pregnant, just as the normal pregnant women are pregnant. However there are dififerences 
even between the two groups showing that something is definitely going on within the 
circulation and in the platelets themselves.
The study discovered that the platelet count and mean platelet volume does not 
change firom non-pregnant women to pregnant women, with or without preeclampsia. It 
also does not change between normal pregnancy and preeclamptic pregnancies. This 
supports the previous research discovered by Konijnenberg et al in February and August 
of 1997.
In looking at CD 41, a resting platelet marker, it is seen that normal pregnant 
women had more CD 41 present than both the non-pregnant and the preeclamptic groups. 
This may be due to the normal hypercoaguable state of pregnancy. However the decrease 
of platelet presence in preeclamptic subjects may be due to the platelets being used up by 
activation, leading to the bleeding problems some women with preeclampsia develop.
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The decreased binding of antibody CD41 could also possibly be explained by the 
increased activation of platelets in preeclampsia. When platelets are activated the 
glycoprotein Ub/IIIa binds calcium, undergoes a conformational change, and 
subsequently binds fibrinogen. It could be hypothesized fiom the results of this study that 
the decrease in CD 41 presence in preeclamptic subjects is due to binding of fibrinogen 
secondary to activation. Since fibrinogen is using up the glycoprotein that CD 41 
normally binds to, there is no place for CD 41 to bind on these activated cells. This 
hypothesis could be proven by studies looking at fibrinogen binding to the platelet.
When platelet activation was looked at, using CD 62 -  a maricer for platelet 
activation, it was noted that the peak and mean presence o f CD 62 was not statistically 
significant amongst any of the groups. However the difference in mean CD 62, looking 
at the actual quantity of cells activated, between non-pregnant and normal pregnant is a 
p-value o f0.0545, which is nearly statistically significant. This tells us that the quantity 
of the activation protein on the platelets activated is nearly, but not quite, statistically 
significant between non pregnant and normal pregnant women. The possible reasons for 
this will be discussed in the limitations section below. However, it is also noted that 
there is no statistical significance between the non-pregnant and the preeclamptic 
pregnant women in the mean amount of cells activated (p-value 0.168). This is an 
interesting finding because these preeclamptic women are pregnant and should have 
similar values to the normal pregnant making them nearly statistically significant as well. 
This is not the case.
The p-value looking at peak CD 62, the amount of fluorescence (or activity) in the 
activated cells, between non-pregnant and preeclamptic is 0.063, which is also nearly
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statistically significant. This value looks at how much the cells are activated rather than 
how many cells are activated. Looking at all o f the data tells us that the normal pregnant 
women have slightly more activation than the non-pregnant women. The preeclamptic 
women have an even larger amount of activation fiom the pregnant women and because 
of that they have quite a bit more activation than the non-pregnant who were less than the 
normal pregnant. This value is not quite statistically significant, however.
The percent o f platelets expressing CD 62, however, was statistically significant. 
There was a statistically significant difference between non-pregnant and preeclamptic 
pregnant women with a p-value o f0.000. This tells us that the percent of platelets that 
are activated, compared to the total number of platelets present, is increased in women 
with preeclampsia. However, there was not a statistically significant difference between 
preeclamptic and normal pregnant subjects. This supports the hypothesis that platelets are 
more activated in preeclamptic women.
Applications
The results of this study can be used to continue to look for a better test to predict 
preeclampsia and to predict bleeding problems in women with preeclampsia. Also, 
women who are currently found to have an increased percentage or level of activation of 
their platelets who are not diagnosed as preeclamptic could be watched more closely for 
the development of preeclampsia. This study is a step in the right direction in looking for 
better ways to predict and prevent the serious disorder of preeclampsia.
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Limitations
The largest limitation o f this study was the small sample size o f preeclamptic 
patients. With only 6 patients to compare to the 22 and 18 of the non-pregnant and 
preeclamptic groups respectively the comparisons were difficult to make and the statistics 
were more difficult to compare. Also, with having only 6 preeclamptic patients, the one 
outlier (whose values were quite different firom the rest of the group) cause a large 
variation.
Another limitation is the small sample size total. With only 46 total patients it is 
difficult to generalize the findings to the population. The small size of all o f the groups 
lead to the means o f the data having a large standard deviation due to outliers.
The reason that the values for CD 62 peak and mean were not statistically 
significant brings us back to the actual data fix>m the statistical analysis. This shows us 
there are some individuals who are outliers, whose data is not consistent with the results 
of the rest o f the individuals in the group. Had these outliers not been included in the 
study the statistical significance of these groups would have been great. Also, had the 
sample size for the groups been larger, the outliers would have averaged in better because 
there would also be outliers in the other direction along the bell curve.
In the normal pregnant group, when looking at the mean CD 62 analysis, there is 
one subject with 227 mean CD 62. This may throw the rest of the group, most of which 
are under 100, off track. In the preeclamptic mean CD 62 group one individual has a 
mean CD 62 o f 110 while the other 5 are in the range of 47-71. Also in the non-pregnant 
group there was one individual with a CD 62 mean o f388 while the rest of the non­
pregnant individuals were below 100, with most being less than 25.
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At the same time, when looking at the CD 62 peak group o f preeclamptic subjects, 4 of 
the 6 have peak values less than 25, but two have values of 64 and 78, which are not 
consistent with the rest of the group. The non-pregnant individuals all have peak CD 62 
that is less than 20 except for two, one which is 22 and not that far off the rest of the 
group, and one that is 81, a far cry from the consistency of the rest o f the group. The 
normal pregnant peak values are very much in line with each other.
Looking at the raw data for CD62 percent the non-pregnant group is consistently 
less than 2 with the exception of one individual. The normal pregnancy group ranges 
from 0.32% and 59.15%, with most o f the individuals in the teens to 30’s. The 
preeclamptic group however appears to have an obvious outlier. While 4 of the 6 
individuals have CD 62 percentage values greater than 25% and one of the 6 has a value 
of 23% (almost to the 25%), there is one individual with only 3% of her platelets 
activated. Had this outlier been excluded, or had there been more individuals in the study 
to bring the mean up to above 25% seen in the majority of the subjects, this would have 
made the percent o f activated platelets more significant.
In comparing the limitations o f this study to the limitations of other studies in this 
arena of medicine it is noted that the limitations are similar. While the sample population 
in this study is small, the sample population of Knijnenberg et al in 1997 was 20 (10 
preeclamptic and 10 normotensive pregnant women). This is a common limitation when 
woridng with human subjects.
Suggestions for Future Research 
Further research could repeat this study and continue it for a longer period of time 
to allow more subjects to be studied. A larger subject population would allow for many
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of the limitations of the study to be overcome and could look for a trend that is more like 
the general population. Outliers would not be as big of a problem in a larger study 
because they would be equaled out by the outliers in the opposite direction. A longer 
period of time would allow more women to be studied.
One area of research that could be looked at is in the realm of a predictive test. A 
large sample of pregnant women could be followed with blood draws every 4-6 weeks in 
the 2"*^  trimester and every 2-4 weeks in the 3"" trimester to look at the activation of 
platelets. These women could be followed closely for the development of preeclampsia. 
The platelet activation could then be compared to the development of preeclampsia to see 
if there is any predictive value in the test.
Further research could also assess whether or not preeclampsia can be predicted in 
the early second trimester in a similar way. Women who have their blood drawn early, 
mid, and late second trimester could be followed for the development of preeclampsia. If 
preeclampsia can be detected earlier research could continue to look for a way to prevent 
preeclampsia and eclampsia firom occurring. Also these women who are at higher risk 
could be treated with current or future treatment methods.
Another aspect that further research could look at is the aspect of prediction of 
bleeding. Women in the study would need to be followed with blood draws before twenty 
weeks, at twenty weeks, after twenty weeks, just before delivery, and after delivery. The 
platelets could be looked at for activation at these various times to see if the activation 
increases during the pregnancy. Also these women could be followed for bleeding 
complications in delivery and the activations of platelets could be compared to the actual 
occurance o f bleeding complications in pregnancy. In this way it could be seen whether
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or not activation of platelets at a certain time, or above a certain percent of the platelets, 
could be predictive of bleeding problems.
Conclusions
With preeclampsia being such a serious disease, leading to 76,000 deaths each 
year world-wide and affecting two to ten percent o f all pregnancies in the United States 
(Barron et al 2000, Konijnenberg A et al 1997, Cunningham 1997, Redman 1992) 
something must be done to lead earlier diagnosis, better treatments, and prevention of 
complications such as bleeding.
This study, similar to other studies, showed an increased activation in pregnancy 
and preeclampsia. It continued to show pregnancy as a hypercoaguable state. It also 
demonstrated a difference in the platelet markers and activation markers between normal 
pregnancy and preeclampsia. This information needs to be looked into further to discover 
the pathogenesis behind why the platelet changes from normal pregnancy to 
preeclampsia.
In conclusion, this study is an excellent stepping-stone for other, longer, more 
complete and comprehensive studies. More studies need to be done to look for a 
predictive test for preeclampsia and for the bleeding problems commonly associated with 
it.
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mSpectrum Health
Butterworth Campus
lUO MICHIGAN STREET NE GRAND RAPIDS Ml 49503-2560
6i6 3911774 FAX 391 2745 www.spectruni~health.org
March 6,2002
Theresa Baguley,RN, PhD
Grand Rapids Medical Education and Research Center for Health Professions 
1000 Monroe NW 
Grand Rapids, MI 49503
Dear Theresa.
At llie March 5,2002 meeting of the Spectrum Health Research & Human Rights 
Committee your project "Clinical Investigation on the Assessment of Platelet Structure 
and Function in Normal and Preeclamptic Patients" (Spectrum Health #1994-010) was 
reviewed and given annual reapproval.
The Research and Human Rights Committee and the F.D.A. requires you submit in 
writing, a progress report to the Committee by February 1,2003 and you will need 
rcapproval should your study be ongoing at that time.
Please be advised that any unexpected serious, adverse reactions must be promptly 
reported to the Research and Human Rights Committee within (5) five days and all 
changes made to the study after initiation require prior approval o f the Human Rights 
Committee before changes are implemented.
If you have any questions, please phone me or Linda Pool at 39I-1291M299.
Sincere!
JcTTr^^. Jones, M.D.
Chairman, Spectrum Health Research & Human Rights Committee
JSJ/tJv
c:
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INFORMED CONSENT INFORMATION FOR THE 
CLINICAL INVESTIGATION ON THE ASSESSMENT OF 
PLATELET STRUCTURE AND FUNCTION 
IN NORMAL AND PREECLAMPTIC PATIENTS
IntrodnctioB
Platelets play a significant role in the prevention of bleeding. During blood vessel injury, 
platelets adhere to the site o f injury and form a platelet plug. The platelet plug efifectively 
forms a seal at the site of injury. A deficiency in the number o f platelets or in the ability 
o f platelets to form a platelet plug results in excessive bleeding even in the event o f minor 
trauma. In a pregnancy complicated ly  preeclanysia there is a  high incidence o f 
thrombocytopenia, low platelet count It has not been determined the exact nature o f the 
thrombocytopenia. Therefore, your participation the study may help in determining the 
cause o f the thrombocytopenia as well as aid in the prediction o f inqiending 
complications.
Purpose and Results of the Research
The purpose o f this study is to analyze both the function and structure of blood platelets 
from normal and preeclanptic pregnant females. The result o f the platelet studies will be 
used to identify changes in preeclamptic females, which could be used to predict 
subsequent complications and to aid in the future treatment in preeclamptic females.
Procedures
There will be approximately 240 particpants in the study. As a participant, you will have 
6 ml of blood removed via venipuncture. You may be asked to return 6-12 weeks after 
the delivery o f your baby for txaseline analysis
Potential Benefits
The benefits o f this study include a contribution to the overall understanding on platelet 
structure and function in preeclamptic females, which may result in changes in the 
treatment of platelet disoMers during preeclampsia.
Potential Risks
The associated risks o f venipuncture include a bruise at the site o f puncture, inflammation 
of the vein and/or infection. In accordance with Michigan Law, an HIV and Hepatitis test 
may be performed on you without written consent if a healthcare woricer/researcher is 
eiqwsed to the blood. If the results o f an HIV or Hepatitis test indicate that you are HTV 
or Hepatitis infected, you will be informed o f these results and provided with the 
appropriate counseling.
Patiat Luitials
Study Partkipation and Medical Records Access
You have the right to refiise participatioa in the study (therein lefiising to this
consent fonn) if so desired, without any fear of prejiuiice to additional treatment. In 
addition, you may refuse to continue on this study at any time after the start of ther^y 
without o f prejudice to additwnai treatment. In case o f a problem or emergeiKy, you
can reach Dr. R. Jeksma at (616) 774-7036 or call Dr. Theresa Bacon-Baguley at (616) 
233-6505.
The doctor and/or his representative at Spectrum Health may inspect your medical 
records for information purposes udiere qspropriate and necessary via mail, FAX or in 
person. Your confidentiality will be protected to the extent permitted by law. Your name 
will not be revealed in any publications or presentation resulting from this study without 
you erqxessed written consent.
Questions regarding your r%hts as a participant can be answered by calling the Spectrum 
Health Research & Human Rights representative, Linda Pool, at the following number; 
(616)391-1291/1299.
Financial Rcsponsibility/Sta«ty Related Personal Injury
You will receive no payment for your partkÿation in the study. Costs associated with 
any injury will not be covered by the investigator or by Spectrum Health Downtown 
Canq)us. Your signature on the consent form indicates that you have volunteered to 
participate in the study and have read the information provided.
Conclusiorrs
I have read this informed Consent and agree to participate in this research study by 
signing this form. By signing this form, 1 have not waived any of the legal rights 1 
otherwise would have as a patient 1 will be provided with a signed copy of this consent 
form and my signature indicates that I have volunteered to participate in this study having 
read the information provided.
Signature of Patient Date
Signature of Investigator Date
Signature of Witness Date
Revised 1/02
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SUBJECT NUMBER 
DATE BLOOD DRAWN] 
DATE BLOOD ANALYZED
FLOW CYTOMETRIC ANALYSIS OF PLATELET 
STRUCTURE IN NORMAL AND HYPERTENSIVE 
PREGNANT FEMALES 
SUBJECT CHARACTERISTICS
Patient H) Number 
Patient Age:
Prior pregnancies: 
Number of live births: 
EDC(Pregnant subjects): 
Subject Group
Non-Pregnant 
Normal Pregnant 
PIH
Preeclanqrsia
Eclanysia
OAer
Medical History No Yes Explain
Allergies_________________ ___ ___ ______
Bleeding disorders _
Diabetes _
Cardiovascular Disease _
Smoker _
Other Significant Medical History
Medications(Over the counter & Prescriptive):
Pregnancy Outcome
  Normal Vaginal Delivery
  C-Section
  Delivery complications (explain)
Postpartum corrylications:
